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was detected but there was tendency for LKB1 mutations occuring in 
smokers vs. non-smokers (p = 0.29). Furthermore, the outcome of stage 
I-II NSCLC patients treated with surgery alone did not differ based on 
LKB1 mutation status. K-Ras mutations were detected in thirty-two 
(19%) of tumor specimens with seven (21% of the K-Ras mutants) of 
these occurring concurrently with LKB1 mutations which, however, 
was statistically insigniﬁcant (p = 0.14). Three B-Raf mutations were 
detected but none of these occurred concurrently with LKB1 muta-
tions. Twenty-eight EGFR mutants (17%) were found with only one of 
them occurring concurrently with LKB1 mutation, which was missense 
outside the kinase domain of LKB1 (p = 0.13).
Conclusions: Mutations of LKB1 gene occur frequently in NSCLCs 
from Caucasian origin. There is tendency of coexistence in LKB1 and 
K-Ras mutations and exclusivity in LKB1 and EGFR mutations but 
these were statistically insigniﬁcant with our limited tumor material. 
Further studies are validated to clarify the outcome of LKB1 and K-Ras 
double mutation NSCLC patients and effect of LKB1 mutations to 
therapeutic responses in NSCLC. 
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Background: p53 intracellular poll is regulated by both MDM2 
induced degradation and p14ARF inhibition of MDM2-p53 complex 
formation. It was commonly accepted that p14ARF inhibits MDM2-
p53 complex by sequestering MDM2 in nucleoli. However in recent 
models, nucleophosmin (NMP) might sequester p14ARF in nucleoli 
preventing its inhibition of nucleoplasmic MDM2.
We studied whether MDM2, p14ARF and NPM expressions are modi-
ﬁed during early squamous carcinogenesis, the time course of appear-
ance of these abnormalities and relative intracellular localizations of 
these proteins.
Methods: 179 biopsies, including normal tissue, all type of bronchial 
preneoplastic lesions and early lung cancer were assessed for MDM2, 
p14ARF and NPM expressions using immunohistochemistry. 132 biop-
sies were evaluable for all three markers. 
Abnormal expression was deﬁned as follows: for MDM2, increased 
expression based on a score including intensity and number of positive 
cells (Eymin, 2002), for p14ARF, expression <10% or relocalization 
from the nucleoplasm to nucleoli in ≥10% of cells, for NMP, disappear-
ance from the nucleoplasm and concentration in nucleoli in ≥10% of 
cells.
Triple immunoﬂuorescent staining with antibodies directed against 
p14ARF, MDM2 and p53 (13 biopsies) and p14ARF, MDM2 and NPM 
(11) were performed, followed by laser scanning confocal microscopy.
Results: 
1) Expression
Aberrant expression was observed for all three proteins in lung preneo-
plastic lesions.
Protein
Type of  
abnormality
Histo-
pathological 
cut-oﬀ
Number of 
biopsies with 
aberrant 
expression
Number of 
biopsies with 
aberrant 
expression
p
   < cut-oﬀ = or > cut-oﬀ  
MDM2 overexpression mild dysplasia 22/94 (23%) 67/85 (79%) < 0.001
NPM relocalization  to nucleoli
moderate 
dysplasia 4/75 (5%) 16/61(26%) 0.034
p14ARF loss of  expression (1)
severe 
dysplasia 19/100 (19%) 23/44 (52%) 0.013
p14ARF relocalization  to nucleoli (2)
severe 
dysplasia 5/81 (6%) 8/21 (38%) < 0.001
p14ARF
aberrant 
expression  
(1) or (2)
severe 
dysplasia 24/100 (24%) 31/44 (70%) < 0.001
 
Aberrant p14ARF expression was statistically associated with MDM2 
overexpression: 75% and 85% of biopsies showing p14ARF loss or 
relocalization overexpressed MDM2.
2) Localization
Immunohistochemistry indicated that relocalizations of NPM and 
p14ARF to nucleoli were associated (p<0.001): 77% of biopsies ex-
pressing relocalized p14ARF showed relocalized NPM.
Immunoﬂuorescent staining indicated that MDM2 and p53 were local-
ized in the nucleoplasm of bronchial epithelial cells, excluding nucleoli.
Three patterns were observed for p14ARF: 1) not detected, 2) ex-
pressed either in nucleoli, 3) either in the nucleoplasm alone. 
Two patterns were observed for NPM: 1) present in nucleoli only, in 
which NPM colocalized with p14ARF but not with MDM2, 2) present 
both in nucleoli and in the nucleoplasm, in which NPM colocalized 
with nucleoplasmic p14ARF.
Conclusions: Our data suggest that MDM2, NPM and p14ARF could 
all play an active role early in lung squamous carcinogenesis: MDM2 
is already aberrantly expressed at the grade of mild dysplasia. p14ARF 
loss of expression or its relocalization from the nucleoplasm to nucleoli 
was associated with increased MDM2 expression. Both NMP and 
p14ARF, but not MDM2, are relocalized to nucleoli, supporting the 
hypothesis that relocalization of p14ARF in nucleoli might impair 
p14ARF-MDM2 complex formation.
